Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
NCT02568683 · Gilead Sciences · PHASE1/PHASE2 · terminated · last registry update 2019-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-08Results posted on the registry: Gilead Sciences, Lanraplenib + Filgotinib (NCT03134222)
- 2020-03-06Results posted on the registry: Gilead Sciences, Entospletinib + Daunorubicin (NCT03135028)
- 2020-03-06Also stopped (terminated): Gilead Sciences, Entospletinib + Daunorubicin (NCT03135028)
- 2020-02-28Results posted on the registry: Gilead Sciences, Tirabrutinib + Entospletinib (NCT02983617)
- 2020-01-22Results posted on the registry: Gilead Sciences, Lanraplenib + Filgotinib (NCT03100942)
- 2020-01-02Also stopped (terminated): Gilead Sciences, Entospletinib + Vincristine (NCT02404220)
- 2019-12-02Results posted on the registry: Gilead Sciences, Entospletinib + Vincristine (NCT02404220)
- 2019-11-15Results posted on the registry: Gilead Sciences, Entospletinib + Daunorubicin (NCT02343939)
- 2019-11-15Also stopped (terminated): Gilead Sciences, Entospletinib + Daunorubicin (NCT02343939)
- 2019-10-25Phase 3 first posted: Rigel Pharmaceuticals, Fostamatinib disodium (NCT04138927)
- 2019-10-25Results posted on the registry: Gilead Sciences, Lanraplenib. (NCT02959138)
- 2019-10-18Phase 3 first posted: Kissei Pharmaceutical Co., Ltd., R788 + Placebo (NCT04132050)
- 2019-07-26Results posted on the registry: Gilead Sciences, Entospletinib (NCT02521376)
- 2019-07-16Phase 3 first posted: Portola Pharmaceuticals, Cerdulatinib (NCT04021082)
- 2019-06-27Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib 150 mg + Fostamatinib 100 mg (NCT02112838)
- 2019-01-25Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib Disodium + Placebo (NCT02076412)
- 2019-01-11Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib disodium + Placebo (NCT02076399)
- 2018-12-26Results posted on the registry: Gilead Sciences, ENTO + Placebo (NCT02701634)
- 2018-12-26Also stopped (terminated): Gilead Sciences, ENTO + Placebo (NCT02701634)
- 2018-12-05Phase 3 first posted: Rigel Pharmaceuticals, Fostamatinib disodium + Placebo (NCT03764618)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision